北京商报讯（记者 陶凤 王天逸）近日，美湖股份披露投资者关系活动记录表并在互动平台回复投资者 称，公司为客户配套的减速器关节模组零部件已按客户要求正常量产交付。公司目前具备年产500万套 齿轮、年产320万套电机和年产5万套谐波减速器产能，同时公司参股子公司东嘉智能具备年产200万套 贴片产能。公司积极参与优质客户的同步开发，并根据市场开发进度实施新增产能布局。 具身智能核心零部件项目方面，公司拥有腾讯、银河通用、蚂蚁等十余家头部机器人客户。 ...

Core Viewpoint - Meihua Co., Ltd. (603319.SH) has confirmed that it is meeting customer demands by delivering components for reducer joint modules in normal production volumes [1] Production Capacity - The company has an annual production capacity of 5 million sets of gears, 3.2 million sets of motors, and 50,000 sets of harmonic reducers [1] - The company's subsidiary, Dongjia Intelligent, has an annual production capacity of 2 million sets of surface mount devices [1] Market Development - The company is actively involved in the synchronous development with high-quality customers and is implementing new capacity layouts based on market development progress [1]

Core Viewpoint - The company has successfully transitioned to mass production of components for a leading robotics manufacturer, indicating strong operational capabilities and customer demand [1] Group 1: Company Operations - The company provides reducer joint module components to Y Company (Yushu Technology), a leading robotics manufacturer in Hangzhou [1] - The company has achieved normal mass production delivery of components as per customer requirements [1] Group 2: Production Capacity - The company has an annual production capacity of 5 million sets of gears, 3.2 million sets of motors, and 50,000 sets of harmonic reducers [1] - The company's subsidiary, Dongjia Intelligent, has an annual production capacity of 2 million sets of surface mount devices [1]

Financial Data and Key Metrics Changes - The company is focused on improving R&D as a percentage of sales, aiming to increase it from 8% to 9-10% without sacrificing EPS [11][12] - The management anticipates high single-digit EPS improvement starting in 2027, driven by margin expansion and operational improvements [38][56] Business Line Data and Key Metrics Changes - The company is seeing strong growth in the CAS segment, with growth accelerating from about 30% to almost 50% from Q4 to Q1, driven by the Avera capital systems [59][60] - The diabetes business is expected to improve with the launch of two new sensors, which are anticipated to enhance market competitiveness [49][50] Market Data and Key Metrics Changes - The U.S. TAVR business showed slight growth above 6% in Q1, while international markets performed stronger [83] - The company is optimistic about the Ardian product, expecting significant market development following a favorable CMS announcement [77][78] Company Strategy and Development Direction - The management emphasizes the need to capitalize on current growth drivers and accelerate M&A activities to enhance the portfolio [6][19] - The company is committed to maintaining a diverse portfolio while focusing on high-growth areas such as cardiac ablation and hypertension [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledges past operational challenges but believes they are now in a better position to pursue M&A and drive growth [19][25] - The company is confident in its growth trajectory, particularly in the second half of the year, with several product launches expected to contribute positively [48][88] Other Important Information - The company is addressing gross margin compression through better pricing strategies and operational improvements, with expectations for consistent gross margin improvement over time [28][36] - The management is focused on the upcoming tibial launch, which is anticipated to be a significant growth driver [86][88] Q&A Session Summary Question: What areas does Elliott want to see improvement in? - Management indicated alignment with Elliott's focus on capitalizing on growth drivers and accelerating M&A activities [5][6] Question: Why has the company done less M&A compared to peers? - The management cited operational issues and a focus on strengthening the company's foundation as reasons for the slower pace of M&A [19][25] Question: What is the outlook for the diabetes business? - The management expressed optimism about the diabetes segment, highlighting the upcoming launch of two new sensors as a key growth factor [49][50] Question: How does the company plan to improve gross margins? - The management outlined strategies including better pricing management, cost control, and innovation to drive gross margin improvement [28][36] Question: What is the expected ramp for the Ardian product? - Management is confident in the Ardian product's market potential and is focused on market development following a favorable CMS decision [77][78]